Suppr超能文献

新的 IASLC/ATS/ERS 分类和侵袭性肿瘤大小可预测 I 期肺腺癌的疾病复发。

New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma.

机构信息

Department of Pathology and Laboratory Medicine, Yamagata Prefectural Central Hospital, Yamagata, Japan.

出版信息

J Thorac Oncol. 2013 May;8(5):612-8. doi: 10.1097/JTO.0b013e318287c3eb.

Abstract

INTRODUCTION

The purpose of this study is to analyze and validate the prognostic impact of the new lung adenocarcinoma (ADC) classification proposed by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society and invasive tumor size in stage I lung ADC of Japanese patients.

METHODS

We reclassified 191 stage I ADCs according to the new classification. The percentage of each histological subtype and the predominant type were determined. In addition, both total tumor size and invasive tumor size were examined. The relationship between these results and clinicopathological backgrounds was investigated statistically.

RESULTS

The 5-year disease-free survival (DFS) of adenocarcinoma in situ and minimally invasive adenocarcinoma was 100%; lipidic-predominant ADCs, 94.9%; papillary-predominant ADCs, 85.4%; acinar-predominant ADCs, 89.7%; and solid-predominant ADCs, 54%. The predominant growth pattern was significantly correlated with DFS (p < 0.001, overall). With regard to tumor size, total tumor size was not correlated with DFS (p = 0.475, overall), however, invasive tumor size was significantly correlated with DFS (≤ 0.5 cm/ > 0.5 cm, ≤ 1 cm/ >1 cm, ≤ 2 cm/>2 cm, ≤ 3 cm/ >3 cm, 100%/91.5%/85.9%/80.8%/66.7%% in 5-year DFS) (p = 0.006, overall). A multivariate analysis showed solid-predominant and invasive tumor size were independent predictors of increased risk of recurrence (solid versus nonsolid: hazard ratio = 4.08, 95% confidence interval:1.59-10.5, p = 0.003; invasive tumor size: hazard ratio = 2.04, 95% confidence interval:1.14-3.63, p = 0.016).

CONCLUSION

: The new International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society ADC classification and invasive tumor size are very useful predictors of recurrence of stage I ADCs in Japanese patients.

摘要

简介

本研究旨在分析和验证国际肺癌研究协会、美国胸科学会和欧洲呼吸学会提出的新肺腺癌(ADC)分类以及日本Ⅰ期肺 ADC 浸润性肿瘤大小对预后的影响。

方法

我们根据新分类重新对 191 例Ⅰ期 ADC 进行分类,确定各组织学亚型的百分比和主要类型。此外,还检查了总肿瘤大小和浸润性肿瘤大小。统计分析这些结果与临床病理背景的关系。

结果

原位腺癌和微浸润腺癌的 5 年无病生存率(DFS)为 100%;脂质优势型 ADC 为 94.9%;乳头优势型 ADC 为 85.4%;腺泡优势型 ADC 为 89.7%;实体优势型 ADC 为 54%。主要生长方式与 DFS 显著相关(p<0.001,总体)。关于肿瘤大小,总肿瘤大小与 DFS 无相关性(p=0.475,总体),但浸润性肿瘤大小与 DFS 显著相关(≤0.5cm/>0.5cm,≤1cm/>1cm,≤2cm/>2cm,≤3cm/>3cm,5 年 DFS 中分别为 100%/91.5%/85.9%/80.8%/66.7%)(p=0.006,总体)。多因素分析显示,实体优势型和浸润性肿瘤大小是复发风险增加的独立预测因素(实体型与非实体型:危险比=4.08,95%置信区间:1.59-10.5,p=0.003;浸润性肿瘤大小:危险比=2.04,95%置信区间:1.14-3.63,p=0.016)。

结论

新的国际肺癌研究协会、美国胸科学会和欧洲呼吸学会 ADC 分类和浸润性肿瘤大小是预测日本Ⅰ期 ADC 复发的非常有用的指标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验